/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT
INTENDED FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION
IN THE UNITED STATES/
SAN DIEGO, June 28 /CNW/ - Nventa Biopharmaceuticals Corporation
announced today that it has filed a preliminary prospectus with the securities
regulators in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and
Nova Scotia for a proposed "best efforts" unit offering. Each unit will be
comprised of one common share in the capital of the company and one half of
one common share purchase warrant. Each whole warrant will entitle the holder
to purchase one common share in the capital of the company for 30 months
following closing. The agents of the offering are Jennings Capital Inc. and
Canaccord Capital Corporation.
This news release does not constitute an offer to sell or the
solicitation of an offer to buy the securities in any jurisdiction. The
securities offered have not been and will not be registered under the United
States Securities Act of 1933, as amended, or any state securities laws and
may not be offered or sold in the United States or to U.S. persons unless the
securities are registered or an exemption from such registration is available.
About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock
Exchange under the symbol NVN.
For more information about Nventa Biopharmaceuticals Corporation, please
visit the company's website located at www.nventacorp.com.
For further information:
For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Tel: (858) 202-4900,
Fax: (858) 450-6849, email@example.com